Recent progress on chemical biology of pluripotent stem cell selfrenewal, reprogramming and cardiomyogenesis

Recent Patents on Regenerative Medicine

Volumn 1, Issue 3, 2011, Pages 263-274

  Hao, Jijun ^a   Sawyer, Douglas B ^a   Hatzopoulos, Antonis K ^a   Hong, Charles C ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Research Medicine   (United States)

Author keywords

Cardiomyogenesis; Chemical biology; Differentiation; IPS cells; Pluripotent stem cells; Small molecules

Indexed keywords

EID: 84876510550     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210296511101030263     Document Type: Article

References (111)

1. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: Observations on stem cells and cardiac repair. J Am Coll Cardiol 2006; 47(9): 1777-1785.
2. Hansson EM, Lindsay ME, Chien KR. Regeneration next: Toward heart stem cell therapeutics. Cell Stem Cell 2009; 5(4): 364-377.
3. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005; 111(2): 150-156.
4. Wollert KC. Cell therapy for acute myocardial infarction. Curr Opin Pharmacol 2008; 8(2): 202-210.
5. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11(4): 367-368.
6. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109(12): 1543-1549.
7. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006; 98(11): 1414-1421.
8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
9. Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, et al. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 2007; 110(2): 501-508.
10. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, Hu J, et al. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS One 2008; 3(8): e2904.
11. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005; 118(Pt 19): 4495-4509.
12. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 1988; 336(6200): 688-690.
13. Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988; 336(6200): 684-687.
14. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 1998; 12(13): 2048-2060.
15. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T, et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J 1999; 18(15): 4261-4269.
16. Raz R, Lee CK, Cannizzaro LA, d'Eustachio P, Levy DE. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA 1999; 96(6): 2846-2851.
17. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003; 115(3): 281-292.
18. Cheng J, Dutra A, Takesono A, Garrett-Beal L, Schwartzberg PL. Improved generation of C57BL/6J mouse embryonic stem cells in a defined serum-free media. Genesis 2004; 39(2): 100-104.
19. Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, Frane JL, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24(2): 185-187.
20. Mallon BS, Park KY, Chen KG, Hamilton RS, McKay RD. Toward xeno-free culture of human embryonic stem cells. Int J Biochem Cell Biol 2006; 38(7): 1063-1075.
21. Chen S, Do JT, Zhang Q, Yao S, Yan F, Peters EC, et al. Selfrenewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci USA 2006; 103(46):17266-17271.
22. Chen, S., Ding, S., Yan, F., Schultz, P. Compounds that maintain pluripotency of embryonic stem cells. US20100234400 (2010).
23. Qi X, Li TG, Hao J, Hu J, Wang J, Simmons H, et al. BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2004; 101(16): 6027-6032.
24. Burdon T, Stracey C, Chambers I, Nichols J, Smith A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev Biol 1999; 210(1): 30-43.
25. Paling NR, Wheadon H, Bone HK, Welham MJ. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinasedependent signaling. J Biol Chem 2004; 279(46): 48063-48070.
26. Storm MP, Bone HK, Beck CG, Bourillot PY, Schreiber V, Damiano T, et al. Regulation of Nanog expression by phosphoinositide 3-kinase-dependent signaling in murine embryonic stem cells. J Biol Chem 2007; 282(9): 6265-6273.
27. Welham MJ, Storm MP, Kingham E, Bone HK. Phosphoinositide 3-kinases and regulation of embryonic stem cell fate. Biochem Soc Trans 2007; 35(Pt 2): 225-228.
28. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 2006; 25(19): 2697-2707.
29. Kunath T, Saba-El-Leil MK, Almousailleakh M, Wray J, Meloche S, Smith A. FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from selfrenewal to lineage commitment. Development 2007; 134(16): 2895-2902.
30. Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods 2005; 2(3): 185-190.
31. Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, et al. Longterm self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci USA 2006; 103(18): 6907-6912.
32. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4(1): 33-41.
33. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 2010; 5(2): 245-253.
34. Gonzalez R, Lee JW, Snyder EY, Schultz PG. Dorsomorphin promotes human embryonic stem cell self-renewal. Angew Chem Int Ed Engl 2011; 50(15): 3439-3441.
35. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453(7194): 519-523.
36. Perry, J., Li, L., Grindley, J. Methods and compositions for stem cell self-renewal. US20100196337 (2010).
37. Smith, A., Ying, Q. Culture medium containing kinase inhibitors, and uses thereof. US20080014638 (2008).
38. Aubert J, Dunstan H, Chambers I, Smith A. Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation. Nat Biotechnol 2002; 20(12): 1240-1245.
39. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10(1): 55-63.
40. Ogawa K, Nishinakamura R, Iwamatsu Y, Shimosato D, Niwa H. Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. Biochem Biophys Res Commun 2006; 343(1): 159-166.
41. Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, et al. Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet 2002; 32(4): 594-605.
42. Pereira L, Yi F, Merrill BJ. Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol 2006; 26(20): 7479-7491.
43. Takao Y, Yokota T, Koide H. Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. Biochem Biophys Res Commun 2007; 353(3): 699-705.
44. Wray J, Kalkan T, Smith AG. The ground state of pluripotency. Biochem Soc Trans 2010; 38(4): 1027-1032.
45. Miyabayashi T, Teo JL, Yamamoto M, McMillan M, Nguyen C, Kahn M. Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci USA 2007; 104(13): 5668-5673.
46. Brivanlou, A., Sato, N., Meijer, L. Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime. US20060030042 (2006).
47. Kahn, M. Serum-free expansion of cells in culture. US20070128669 (2007).
48. Smith, A., Burdon, T. Propagation and/or derivation of embryonic stem cells. US7371573 (2008).
49. Brivanlou, A., Sato, N., Meijer, L. Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime. US20060030042 (2006).
50. Batlle-Morera L, Smith A, Nichols J. Parameters influencing derivation of embryonic stem cells from murine embryos. Genesis 2008; 46(12): 758-767.
51. Nichols J, Jones K, Phillips JM, Newland SA, Roode M, Mansfield W, et al. Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nat Med 2009; 15(7): 814-818.
52. Buehr M, Meek S, Blair K, Yang J, Ure J, Silva J, et al. Capture of authentic embryonic stem cells from rat blastocysts. Cell 2008; 135(7): 1287-1298.
53. Li P, Tong C, Mehrian-Shai R, Jia L, Wu N, Yan Y, et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell 2008; 135(7): 1299-1310.
54. Bao S, Tang F, Li X, Hayashi K, Gillich A, Lao K, et al. Epigenetic reversion of post-implantation epiblast to pluripotent embryonic stem cells. Nature 2009; 461(7268): 1292-1295.
55. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F, et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci USA 2010; 107(20): 9222-9227.
56. Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell 2009; 4(6): 487-492.
57. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008; 6(10): e253.
58. Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, et al. Nanog is the gateway to the pluripotent ground state. Cell 2009; 138(4): 722-737.
59. Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007; 448(7150): 196-199.
60. Pera MF, Tam PP. Extrinsic regulation of pluripotent stem cells. Nature 2010; 465(7299): 713-720.
61. Tchieu J, Kuoy E, Chin MH, Trinh H, Patterson M, Sherman SP, et al. Female human iPSCs retain an inactive X chromosome. Cell Stem Cell 2010; 7(3): 329-342.
62. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143(4): 508-525.
63. Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Welstead GG, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 2010; 141(5): 872-883.
64. Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448(7151): 313-317.
65. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322(5903): 949-953.
66. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
67. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448(7151): 318-324.
68. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
69. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322(5903): 945-949.
70. Cho HJ, Lee CS, Kwon YW, Paek JS, Lee SH, Hur J, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010; 116(3): 386-395.
71. Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010; 5(3): 418-428.
72. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-630.
73. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4(5): 381-384.
74. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26(7): 795-797.
75. Huangfu, D., Melton, D., Maehr, R. Efficient induction of pluripotent stem cells using small molecule compounds. US20110014164 (2011).
76. Shi, Y., Desponts, C., Lin, T., Li, W., Zhu, S., Ding, S. Chemical approaches for generation of induced pluripotent stem cells. US20100267141 (2010).
77. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 2(6): 525-528.
78. Ichida, J., Blanchard, J., Lam, K., Rubin, L., Eggan, K. Efficient induction of pluripotent stem cells using small molecule compounds. WO2010033906 (2010).
79. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, et al. A small-molecule inhibitor of tgf-Beta signaling replaces Sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009; 5(5): 491-503.
80. Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009; 6(11): 805-808.
81. Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009; 27(12): 2992-3000.
82. Chen S, Zhang Q, Wu X, Schultz PG, Ding S. Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc 2004; 126(2): 410-411.
83. Chen, S., Ding, S., Schultz, P. Compositions and methods for inducing cell dedifferentiation. US20050176707 (2005).
84. Lee EK, Bae GU, You JS, Lee JC, Jeon YJ, Park JW, et al. Reversine increases the plasticity of lineage-committed cells toward neuroectodermal lineage. J Biol Chem 2009; 284(5): 2891-2901.
85. Anastasia L, Sampaolesi M, Papini N, Oleari D, Lamorte G, Tringali C, et al. Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death Differ 2006; 13(12): 2042-2051.
86. Amabile G, D'Alise AM, Iovino M, Jones P, Santaguida S, Musacchio A, et al. The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts. Cell Death Differ 2009; 16(2): 321-330.
87. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, et al. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 2003; 107(14): 1912-1916.
88. Passier, R., Mummery, C. Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom. US20080254003 (2008).
89. Wu, X., Ding, S., Schultz, P. Compositions and methods for inducing cardiomyogenesis. US20050209231 (2005).
90. Wu X, Ding S, Ding Q, Gray NS, Schultz PG. Small molecules that induce cardiomyogenesis in embryonic stem cells. J Am Chem Soc 2004; 126(6): 1590-1591.
91. Sadek H, Hannack B, Choe E, Wang J, Latif S, Garry MG, et al. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci USA 2008; 105(16): 6063-6068.
92. Olson, E., Frantz, D., Hsieh, J., Mcknight, S.L., Schneider, J. Stem cell differentiating agents and uses therefor. US20090076103 (2009).
93. Moore CS, Mjaatvedt CH, Gearhart JD. Expression and function of activin beta A during mouse cardiac cushion tissue formation. Dev Dyn 1998; 212(4): 548-562.
94. Nakajima Y, Yamagishi T, Hokari S, Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: Roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 2000; 258(2): 119-127.
95. Jones CM, Lyons KM, Hogan BL. Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. Development 1991; 111(2): 531-542.
96. Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev 1995; 9(17): 2105-2116.
97. Johansson BM, Wiles MV. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. Mol Cell Biol 1995; 15(1): 141-151.
98. Gadue P, Huber TL, Paddison PJ, Keller GM. Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. Proc Natl Acad Sci USA 2006; 103(45): 16806-16811.
99. Klaus A, Saga Y, Taketo MM, Tzahor E, Birchmeier W. Distinct roles of Wnt/beta-catenin and Bmp signaling during early cardiogenesis. Proc Natl Acad Sci USA 2007; 104(47): 18531-18536.
100. Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, Pabon L, et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci USA 2007; 104(23): 9685-9690.
101. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, Kikuchi A, et al. Developmental stage-specific biphasic roles of Wnt/betacatenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci USA 2006; 103(52): 19812-19817.
102. Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry CE. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One 2010; 5(6): e11134.
103. Tseng AS, Engel FB, Keating MT. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol 2006; 13(9): 957-963.
104. Koshimizu, U., Tanaka, T., Kawashima, K., Kadokura, M. Method for inducing differentiation of pluripotent stem cells into cardiomyocyte. US20090325288 (2009).
105. Wang H, Hao J, Hong CC. Cardiac induction of embryonic stem cells by a small molecule inhibitor of wnt/beta-catenin signaling. ACS Chem Biol 2011; 6(2): 192-197.
106. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008; 118(5): 507-517.
107. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104(4): e30-e41.
108. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467(7313): 285-290.
109. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28(8): 848-855.
110. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471(7336): 68-73.
111. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142(3): 375-386.